|
Volumn 332, Issue 6026, 2011, Pages 159-160
|
First specific drugs raise hopes for hepatitis C
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALISPORIVIR;
ALPHA INTERFERON;
ANTIVIRUS AGENT;
BOCEPREVIR;
CYCLOPHILIN A;
NONSTRUCTURAL PROTEIN 3;
NONSTRUCTURAL PROTEIN 4A;
PEGINTERFERON ALPHA;
PROTEINASE;
PROTEINASE INHIBITOR;
RIBAVIRIN;
RNA DIRECTED RNA POLYMERASE INHIBITOR;
TELAPREVIR;
VIRUS PROTEIN;
DRUG DERIVATIVE;
N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE;
N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE;
NS3 PROTEIN, HEPATITIS C VIRUS;
NS4 PROTEIN, HEPATITIS C VIRUS;
OLIGOPEPTIDE;
PROLINE;
DISEASE CONTROL;
DISEASE PREVALENCE;
DISEASE TRANSMISSION;
DRUG;
ENZYME ACTIVITY;
HEPATITIS;
INHIBITOR;
VIRAL DISEASE;
VIRUS;
ANEMIA;
ANTIVIRAL RESISTANCE;
ANUS PRURITUS;
ASTRONOMY;
BAD TASTE;
BLOOD TRANSFUSION;
DEPRESSION;
DRUG COST;
DRUG EFFICACY;
DRUG ERUPTION;
DRUG INDUSTRY;
DRUG SAFETY;
DRUG TARGETING;
EGYPT;
EUROPE;
FLU LIKE SYNDROME;
HEALTH CARE PERSONNEL;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
INFECTION RATE;
JAPAN;
LIVER CIRRHOSIS;
NONHUMAN;
PREVALENCE;
PRIORITY JOURNAL;
SHORT SURVEY;
SWITZERLAND;
UNITED STATES;
UNSPECIFIED SIDE EFFECT;
VIRUS REPLICATION;
VIRUS TRANSMISSION;
CLINICAL TRIAL (TOPIC);
DEVELOPING COUNTRY;
DRUG ANTAGONISM;
DRUG APPROVAL;
DRUG COMBINATION;
DRUG EFFECT;
ECONOMICS;
ENZYMOLOGY;
NOTE;
VIROLOGY;
EUROPE;
UNITED STATES;
HEPATITIS C VIRUS;
ANTIVIRAL AGENTS;
CLINICAL TRIALS AS TOPIC;
DEVELOPING COUNTRIES;
DRUG APPROVAL;
DRUG THERAPY, COMBINATION;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
HUMANS;
OLIGOPEPTIDES;
PROLINE;
PROTEASE INHIBITORS;
VIRAL NONSTRUCTURAL PROTEINS;
|
EID: 79953831881
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.332.6026.159 Document Type: Short Survey |
Times cited : (11)
|
References (0)
|